Clinical Trial Update: Furosemide as Supportive Therapy for COVID-19 Respiratory Failure [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates a terminated Phase 2/3 study evaluating furosemide as supportive therapy for COVID-19 respiratory failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Failure

Drugs mentioned

• FUROSEMIDE (Furosemide)

Snippet

Sponsor: Dr. John Muscedere | Conditions: Covid19, Respiratory Failure | Phase 2, Phase 3 | Status: TERMINATED